poisar

Stocks · News reference

Reported Earlier, Royalty Pharma Announced An Update On Novartis’ Phase 3 Results From The Horizon Outcomes Trial For Pelacarsen, An Antisense Oligonucleotide Studied In Patients With Atherosclerotic Cardiovascular Disease And Elevated Lipoprotein(A)

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NVSRPRX
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight

    The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.

    ABBVLLYJNJNVSBMY
  6. Thomas Niel

    Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

    Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.

    RPRXREGNIONSNVSAMGN